Relapsed and refractory Hodgkin lymphoma: transplantation strategies and novel therapeutic options.

Current Treatment Options in Oncology
Kevin A DavidA M Evens

Abstract

Many patients with Hodgkin lymphoma are cured with initial therapy, although a portion of patients will experience primary induction failure or disease relapse. Pathologic confirmation of refractory or relapsed Hodgkin lymphoma is important. Following two to four cycles of non-cross-resistant salvage chemotherapy, the standard of care is high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (HSCT), which is associated with long-term event-free survival rates of 45-68%. Of note, survival rates for studies integrating total lymphoid irradiation into the autologous HSCT-conditioning regimen are among the highest reported for relapsed/refractory Hodgkin lymphoma. Further treatment options are available for patients not fit to proceed to HSCT, for relapsed disease after autologous HSCT, and for 'high-risk' Hodgkin lymphoma including chemotherapy-resistant disease. Allogeneic HSCT is a valid treatment option, as a graft-vs.-Hodgkin-lymphoma effect has been demonstrated. In addition, novel targeted treatments are being investigated such as receptor-specific antibodies, radiolabeled antibodies, antiapoptotic agents including inhibitors of the nuclear factor-kappaB complex or X-linked inhibitor of apoptos...Continue Reading

References

Nov 19, 1992·The New England Journal of Medicine·G P CanellosB A Peterson
Feb 11, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D L LongoV T DeVita
Jan 1, 1995·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·R D PeznerS J Forman
Feb 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J L GajewskiM M Horowitz
Apr 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N MilpiedA H Goldstone
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H M LazarusM M Horowitz
Apr 22, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R W TsangA Keating
Jul 23, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J AparicioM Pastor
Dec 1, 2000·Nature·B VogelsteinA J Levine
Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A SuredaUNKNOWN Grupo Español de Linformas/Transplante Autólogo de Médula Osea Spanish Cooperative Group
Dec 4, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G AkpekR J Jones
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andreas JostingAndreas Engert
Feb 15, 2003·Blood·Bradley C EkstrandSandra J Horning
Feb 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David B DugganBruce A Peterson
Apr 19, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M ConstansUNKNOWN GEL/TAMO Cooperative Group
Aug 22, 2003·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Patrick J StiffUNKNOWN Southwest Oncology Group
Oct 21, 2003·Leukemia & Lymphoma·Katrin ScheinpflugAstrid Franke
Apr 14, 2004·The Journal of Experimental Medicine·Stephan MathasBernd Dörken
Jun 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gianni BonadonnaPinuccia Valagussa
Jul 28, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J CzyzK Warzocha
Dec 22, 2004·The Journal of Experimental Medicine·Catherine M BollardHelen E Heslop
Mar 2, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A SuredaUNKNOWN Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea Cooperative Group

❮ Previous
Next ❯

Citations

Jul 10, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A EngertUNKNOWN ESMO Guidelines Working Group
Aug 24, 2010·Current Hematologic Malignancy Reports·Rachel B SalitSteven Z Pavletic
Jan 6, 2011·Expert Opinion on Investigational Drugs·Heiner AdamsAlexandar Tzankov
Aug 30, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Sarah F KellerJonathan W Friedberg
Jan 27, 2011·Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology·Alexandar TzankovStephan Dirnhofer
Jun 22, 2018·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Irena StepanikovaGinna Laport
Mar 12, 2010·Paediatric Drugs·Jennifer Freed, Kara M Kelly

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.